Denali Therapeutics Inc (DNLI)
20.84
+0.44
(+2.16%)
USD |
NASDAQ |
Jun 04, 10:22
Denali Therapeutics Research and Development Expense (Quarterly): 107.02M for March 31, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 107.02M |
| December 31, 2023 | 107.80M |
| September 30, 2023 | 89.74M |
| June 30, 2023 | 97.52M |
| March 31, 2023 | 128.82M |
| December 31, 2022 | 92.11M |
| September 30, 2022 | 87.79M |
| June 30, 2022 | 92.74M |
| March 31, 2022 | 86.10M |
| December 31, 2021 | 67.88M |
| September 30, 2021 | 71.56M |
| June 30, 2021 | 65.71M |
| March 31, 2021 | 60.21M |
| December 31, 2020 | 54.74M |
| September 30, 2020 | 53.70M |
| Date | Value |
|---|---|
| June 30, 2020 | 53.15M |
| March 31, 2020 | 51.02M |
| December 31, 2019 | 51.55M |
| September 30, 2019 | 52.54M |
| June 30, 2019 | 51.88M |
| March 31, 2019 | 37.40M |
| December 31, 2018 | 39.91M |
| September 30, 2018 | 30.32M |
| June 30, 2018 | 52.13M |
| March 31, 2018 | 20.82M |
| December 31, 2017 | 18.47M |
| September 30, 2017 | 18.52M |
| June 30, 2017 | 19.00M |
| March 31, 2017 | 18.47M |
| December 31, 2016 | 16.73M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
51.02M
Minimum
Mar 2020
128.82M
Maximum
Mar 2023
76.18M
Average
69.72M
Median
Research and Development Expense (Quarterly) Benchmarks
| Halozyme Therapeutics Inc | 19.11M |
| Neurocrine Biosciences Inc | 159.40M |
| AIM ImmunoTech Inc | 1.951M |
| Protalix BioTherapeutics Inc | 2.887M |
| Armata Pharmaceuticals Inc | 8.016M |